The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. About webletz We create powerful, profitable and long-term connections between brands and your customers. Exelixis, Inc. (NASDAQ: EXEL) awaits the FDA's verdict on its sNDA for cabozantinib, which is being evaluated for patients with previously treated advanced hepatocellular carcinoma. The D-day is Monday.

14 Aug 2018 The skilled StockTwits user and VSTM investor “LonoTrader” compiled a The smallest market cap/valuation pre-approval has been Exelixis  12 Dec 2019 Exelixis, Inc. Expected to Post Quarterly Sales of $231.61 Million · Royal Mail PT Lowered to GBX 175. -$0.44 EPS Expected for Merus NV This  15 Jul 2017 Sports Exelixis. Skype Slashdot SMS StockTwits Svejo Symbaloo Bookmarks Threema Trello Tuenti Twiddla TypePad Post Viadeo Viber VK  20 Dec 2017 The FDA has approved a new indication for cabozantinib tablets (Cabometyx, Exelixis, Inc.) for treatment of patients with advanced renal cell 

9/2/2014 · Exelixis will take a charge of $6 million to $8 million in restructuring charges related to the layoff. The workforce will shrink to just 70 employees. Some investors are hoping that Roche, the Swiss drugmaker, might make an offer for Exelixis. The two companies have collaborated on a drug to treat advanced melanoma.

Exelixis is a commercial-stage biotechnology company that has made a splash with its bread-and-butter drug known as Cabometyx. Exploring X T L Biopharmaceuticals (Nasdaq:XTLB) stock? View XTLB's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Analyzing Gilead Sciences (Nasdaq:GILD) stock? View GILD's stock price, price target, dividend, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Analyzing Aclaris Therapeutics (Nasdaq:ACRS) stock? View ACRS's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Exploring Intercept Pharmaceuticals (Nasdaq:ICPT) stock? View ICPT's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Researching Global Blood Therapeutics (Nasdaq:GBT) stock? View GBT's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat.

EXEL closed down 7.59 percent on Friday, November 29, 2019, on 53 percent of normal volume. The bears made the stock sink to a new 52-week low.

Dividend yield shows much a company pays out in dividends each year relative nasdaq neos to its share price. Alkermes PLC ALKS Researching Amarin (Nasdaq:AMRN) stock? View AMRN's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Exploring Vertex Pharmaceuticals (Nasdaq:VRTX) stock? View VRTX's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Analyzing Halozyme Therapeutics (Nasdaq:HALO) stock? View HALO's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Exploring Minerva Neurosciences (Nasdaq:NERV) stock? View NERV's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Researching Deciphera Pharmaceuticals (Nasdaq:DCPH) stock? View DCPH's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. To name a few, Nektar Therapeutics (Nasdaq: NKTR ) procured more than 337% profits; Spectrum Pharmaceuticals (Nasdaq: SPPI ) delivered over 192% gains; Kite Pharma netted 82%; Atara Biotherapeutics (Nasdaq: ATRA ) appreciated +166%.

20 Dec 2019 Real-time trade and investing ideas on Exelixis, Inc. EXEL from the largest community of traders and investors.

20 Dec 2017 The FDA has approved a new indication for cabozantinib tablets (Cabometyx, Exelixis, Inc.) for treatment of patients with advanced renal cell  27 Aug 2018 22 / 12 / 2016 - MISSISSAUGA, ON (Canada). Ipsen Amends Licensing Agreement With Exelixis To Commercialize And Develop Cabozantinib  25 Sep 2019 Choueiri's disclosures include receiving research funds from AstraZeneca, Bayer, BMS, Cerulean, Eisai, Foundation Medicine Inc., Exelixis,  19 Aug 2019 Dr Atkins has disclosed consulting fees from Arrowhead, Bristol-Myers Squibb, Eisai, Exelixis, Merck, Novartis, Roche, and X4P. He also  27 Jun 2019 AstraZeneca/Medimmune; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Exelixis; Genentech/Roche; Gilead; Lilly; Merck and Co., 

EXEL closed down 7.59 percent on Friday, November 29, 2019, on 53 percent of normal volume. The bears made the stock sink to a new 52-week low.

11/15/2019 · Find the latest SEC Filings data for Exelixis, Inc. Common Stock (EXEL) at Nasdaq.com. exelixis inc (exel): * exelixis enters into a clinical collaboration for three phase 3 combination trials for patients with advanced solid tumors. * exelixis inc (exel) - announced collaboration agreement with roche to evaluate cabozantinib in combination with atezolizumab. * exelixis inc (exel) - clinical program will be co-funded by companies. Exelixis earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Exelixis. 12/20/2019 · Exelixis, Inc. Common Stock (EXEL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. 10/25/2017 · Exelixis shows strong market traction for its lead drug Cabometyx. The company has strong pipeline and is working to expand the use of existing products. The company posted consistent revenue growth this year so far.

Dividend yield shows much a company pays out in dividends each year relative nasdaq neos to its share price. Alkermes PLC ALKS Researching Amarin (Nasdaq:AMRN) stock? View AMRN's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat.